<DOC>
	<DOCNO>NCT01596621</DOCNO>
	<brief_summary>The primary objective study determine overall response rate ( ORR ) , include complete response ( CR ) partial response ( PR ) , bendamustine treatment patient indolent non-Hodgkin lymphoma ( NHL ) progress rituximab rituximab-containing therapy .</brief_summary>
	<brief_title>Bendamustine Treatment Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory Rituximab Treatment</brief_title>
	<detailed_description>This multicenter , nonrandomized , open-label , single-agent clinical study conduct China , design investigate use bendamustine treatment Chinese patient relapse , rituximab-refractory indolent NHL . The study consist screen period 4 week , treatment period approximately 24 week ( eight 21-day cycle ) , long-term follow-up period 2 year last dose study drug . Patients expect participate study approximately 2.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients include study follow criterion meet : 1 . The patient document relapse indolent Bcell NHL . Patients follow subtypes indolent NHL eligible study : small lymphocytic lymphoma ( peripheral B cell count &lt; 5000 cells/mm3 ) lymphoplasmacytic lymphoma splenic marginal zone Bcell lymphoma ( ±villous lymphocyte ) extranodal marginal zone Bcell lymphoma mucosaassociated lymphoid tissue type nodal marginal zone lymphoma ( ±monocytoid Bcells ) follicle center lymphoma follicular ( grade 1 , 2 , 3a ) lymphoma 2 . The patient disease document progressed despite rituximab treatment . The patient 's disease consider rituximab refractory follow criterion meet time patient 's treatment history ( progression must document computed tomography [ CT ] scan magnetic resonance image [ MRI ] biopsy ) patient palpable lymph node well document size , rituximab treatment , palpable disease remain come back [ CT , MRI , biopsy prefer perform whenever possible document progressive disease ( PD ) ] : rituximabonly regimen : Patients receive full course singleagent rituximab ( least 2 dos 375 mg/m2 [ therapeuticallyactive dose ] weekly ) response ( obtain PR good ) treatment progress full regimen rituximab give . rituximab maintenance therapy extend schedule : Patients history full course rituximab ( least 2 dos 375 mg/m2 [ therapeuticallyactive dose ] single agent [ weekly ] combination chemotherapy [ day 1 4 cycle ] ) maintenance regimen , progress next schedule rituximab dose complete maintenance rituximab regimen . rituximabchemotherapy combination regimen : Patients receive full course rituximab ( least 2 dos 375 mg/m2 therapeuticallyactive dose [ day 1 2 cycle ] ) combination chemotherapy response ( obtain PR good ) treatment progress last dose rituximab regimen . full rituximab exposure treatment : Patients history full course rituximab treatment ( least 2 dos 375 mg/m2 [ therapeuticallyactive dose ] single agent combination chemotherapy ) , subsequent rituximab/chemotherapy combination regimen , response ( obtain PR good ) treatment progress last dose rituximab give regimen , even subsequent regimen include less 2 dos rituximab . Patients could receive additional systemic treatment qualify rituximab regimen . 3 . The patient receive treatment least 1 , 3 , previous chemotherapy regimen . A regimen define new treatment combination agent . Retreatment identical regimen agent count new regimen ; however , change cyclophosphamide , vincristine , prednisolone ( CVP ) cyclophosphamide , doxorubicin , vincristine , prednisolone ( CHOP ) count new regimen . Rituximab , radioimmunotherapy , biologic treatment combine chemotherapy count regimen . 4 . The patient bidimensionally measurable disease least 1 lesion measure 2.0 cm single dimension . Patients previous involvedfield irradiation include , provide irradiated area source measurable disease . 5 . The patient least 18 year old time inform consent . 6 . The patient WHO performance status 0 , 1 , 2 . 7 . The patient absolute neutrophil count ( ANC ) 1000 cells/mm3 platelet count 85000 cells/mm3 . 8 . The patient creatinine clearance 30 mL/min determine CockcroftGault calculation . 9 . The patient adequate hepatic function ( 2.5 time ULN aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) , 1.5 time upper limit normal range ( ULN ) total bilirubin ) . Patients nonclinically significant elevation bilirubin due Gilbert 's disease eligible . 10 . The patient bone marrow biopsy within 6 week 1st dose bendamustine . 11 . Women childbearing potential ( surgically sterile 1 year postmenopausal ) must use medically accept method contraception must agree continue use method start 2 week start study drug treatment , study drug treatment , 3 month end study drug treatment . Acceptable method contraception include abstinence , barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . 12 . Women childbearing potential must negative serum urine pregnancy test . 13 . Men surgically sterile capable produce offspring must practice abstinence use barrier method birth control , must agree continue use method start 2 week start study drug treatment , study drug treatment , 3 month end study drug treatment . 14 . The patient estimate life expectancy least 3 month . 15 . The patient ( patient 's legal representative ) provide write informed consent . Patients exclude participate study 1 follow criterion meet : 1 . The patient receive previous radiotherapy , radioimmunotherapy , chemotherapy , immunotherapy within 4 week day 1 cycle 1 fail recover ( Common Terminology Criteria Adverse Events [ CTCAE ] toxicity grade 1 2 ) clinically significant nonhematologic adverse event due agent administer previously . 2 . The patient receive treatment investigational agent within 4 week day 1 cycle 1 . 3 . The patient receive hematopoietic growth factor within 4 week day 1 cycle 1 . However , patient receive chronic erythropoietin treatment eligible inclusion study . 4 . The patient history previous highdose chemotherapy allogeneic stem cell support ( history autologous stem cell support permissible ) . 5 . The patient receive receive treatment therapeutic dos systemic steroid within 4 week day 1 cycle 1 . ( Low dose chronic steroid [ prednisone equivalent ] 20 mg/day nonneoplastic disorder indication lymphoma lymphomarelated complication permit . ) 6 . The patient transform disease . 7 . The patient history central nervous system ( CNS ) leptomeningeal lymphoma . 8 . The patient , within past 5 year , active malignancy target cancer . The exception prostate cancer ( Gleason grade &lt; 6 prostate specific antigen ( PSA ) level within normal range ) , situ cervical breast carcinoma , nonmelanoma skin cancer receive definitive treatment . 9 . The patient pregnant lactate woman . ( Any woman become pregnant study withdrawn study immediately . ) 10 . The patient serious infection , medical condition , psychiatric condition , opinion investigator , might interfere achievement study objective . 11 . The patient know positive human immunodeficiency virus ( HIV ) , active hepatitis B , active hepatitis C ( antihepatitis C virus [ HCV ] positive ) . Hepatitis B surface antigen must test . The determination active disease leave Investigator . 12 . The patient know hypersensitivity mannitol . 13 . The patient use bendamustine previously .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bendamustine hydrochloride</keyword>
	<keyword>CEP-18083</keyword>
	<keyword>Treanda®</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
</DOC>